Nasdaq
$0.5300▲ 0.88%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $99.1MShares out 1.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
30- 10.13Regular26.10.14 01:47SCHEDULE 13GOwnership#●●●
Outlook Therapeutics, Inc.
Empery Asset Management, LP and Ryan M. Lane have entered into a joint filing agreement regarding their Schedule 13G statement for Outlook Therapeutics, Inc. This agreement confirms that both parties hold shares in the company and will jointly file all subsequent amendments to the Schedule 13G.…more
$0.5300+0.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30After-hours26.10.01 05:308-KKey event
Outlook Therapeutics, Inc.
Outlook Therapeutics has received a notification of non-compliance with Nasdaq's minimum bid price rule (Rule 5550(a)(2)) after its common stock closed below $1.00 for 30 consecutive business days. The company has until March 24, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.…more
$0.5300+0.88%vs prev closeView filingShare - 9.18After-hours26.09.19 05:308-KKey event
Outlook Therapeutics, Inc.
Outlook Therapeutics has established the wholesale acquisition cost for its drug LYTENAVA in the United States at $485 per vial. This pricing decision marks a strategic step toward the commercial launch of the product.…more
$0.5300+0.88%vs prev closeView filingShare
29 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Pre-market26.10.09 21:30#●●●#●●●
Outlook Therapeutics Appoints Greg DiPasquale as Chief Commercial Officer…more
Outlook Therapeutics has appointed industry veteran Greg DiPasquale as Chief Commercial Officer to lead the U.S. commercialization of its retinal disease treatment, LYTENAVA. The company is preparing for a U.S. market launch before the end of 2026.…more
$0.5300+0.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.6Pre-market26.10.06 22:20
●●●●●●●● ●●●●● ●●●●●●
Outlook Therapeutics introduced new CFO Kevin Lundquist and discussed the company's transition into a commercial-stage firm following the FDA approval of LYTENAVA. The management team is now focused on executing the U.S. commercial launch and building long-term shareholder value.…more
$0.5300+0.88%vs prev close - 10.1Pre-market26.10.01 22:01
●●●●●●●● ●●●●● ●●●●●●
Outlook Therapeutics has submitted an application to the CMS for a permanent J-code to streamline billing and reimbursement for its ophthalmic drug, LYTENAVA. This move is part of the company's strategy to support its planned U.S. commercial launch by the end of 2026.…more
$0.5300+0.88%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report